Navigation Links
Where tumor cells boldly go: Weill Cornell cancer biologists shed light on the metastatic niche
Date:5/1/2009

NEW YORK (May 1, 2009) -- Traditionally, cancer biologists have embraced a simple and direct model of the disease process: The tumor -- the "seed" -- was seen as bearing total responsibility for the spread of cancer to distant tissues -- the "soil" in which the seed embedded itself, grew, and reproduced. The result was a seed-dominant model that determined the way doctors treated cancer, using strategies targeting the tumor seed but neglecting the role of the soil.

Recently, however, some researchers have been focusing on the permissive microenvironment, or the metastatic niche, that forms in particular tissues located far from the primary tumor, well before full metastasis takes hold.

"In cancer, it is metastatic disease that causes morbidity and mortality," says Dr. David Lyden, co-author of an article in the April 2009 issue of Nature Reviews Cancer.

"At our lab, we're developing a strategic approach to studying metastasis. Our goal is ultimately to be able to predict and pre-empt the process -- early, if possible, but even in advanced metastasis," adds Dr. Lyden, the Stavros S. Niarchos Associate Professor in Pediatric Cardiology, an investigator in the Division of Pediatric Hematology and Oncology, and associate professor of cell and development biology at Weill Cornell Medical College.

Led by Dr. Lyden, a team of researchers is looking at the molecular and cellular players that mediate changes at future sites of metastasis such as liver, lung, brain or bone, and thereby direct the migration patterns of tumor cells.

The group has zeroed in on several of these essential players, including bone marrow-derived cells and growth factors secreted by the tumor itself. These, Dr. Lyden explains, instruct the pre-metastatic niche to get ready for a long visit, one that will require comfortable accommodations for a rapidly growing population of permanent guests.

If the pre-metastatic niche does the tumor's bidding and boosts production of inflammatory chemokines and fibronectin, among other cancer-friendly proteins, a secondary tumor has a good chance of forming -- and thriving.

Dr. Lyden believes his lab's discoveries could open doors leading to the development of new cancer treatments that target each step along the metastatic pathway. "We can envision a time in the not-too-distant future when we'll be able to prevent metastasis through a new approach for early detection and treatment," he says. "That's why we're studying the earliest changes in the pre-metastatic niche in such depth.

"At the same time," he continues, "the challenge is to understand metastasis in its entirety by familiarizing ourselves with the shifting molecular and cellular microenvironment at each step along the way. The ramifications of this approach for cancer treatment, we believe, are inestimable."

The Lyden lab at Weill Cornell was one of seven to be represented in the current issue of Nature Reviews, which is devoted exclusively to the subject of cancer metastasis in a special issue. In their article titled "The Metastatic Niche: Adapting the Foreign Soil," Dr. Lyden and lead author Dr. Bethan Psaila, a Fulbright Fellow in the Lyden lab, summarize the discoveries and insights they've gleaned over the past decade.

"The 'seed and soil' hypothesis is considered one of the most important among cancer biologists, but our lab -- especially in collaboration with Dr. Rosandra Kaplan and the lab of Dr. Shahin Rafii -- was actually first to address it in real terms," Dr. Lyden says. "Now, many other labs are moving in this direction, and all of them are opening up highly promising new avenues for inquiry."

Preventing and treating cancerous tumors will continue to be central to cancer treatment strategy, he adds. But soon, we may begin to see new strategies aimed at disarming the real killer: metastatic disease.


'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. Plastic Surgery 2007: Where Truth Behind Emerging Cosmetic Treatments Meets Amazing Reconstructive Advances
2. Quality Function Excellence: Is Your Money Spent Where It Matters Most?
3. Where Are You Going to Get Your Flu Shot This Season?
4. Key Cleaning Solutions Products Utilized to Combat Community Acquired - MRSA (CA-MRSA) Are Succeeding In Killing Superbugs Where Normal Cleaning Practices and Products Are Not
5. Aetna Reminds Members Affected by California Wildfires Where to Call for Help
6. The Reality of Pregnancy in Sub-Saharan Africa: Author Shares Truth About Pregnancy in a Region Where 1 in 16 Women Die from Complications
7. Where vets served affects frequency of ER visits but not hospital stays
8. Carnegie Mellon study identifies where thoughts of familiar objects occur inside the human brain
9. Stem Cells Modified to Home in Where Theyre Needed
10. G&L Guitars Phyllis Fender Brings Smiles to Children Everywhere
11. Progress toward an alternative for EPO: Gas6 offers remedy where EPO fails today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Engineers at ... bio-compatible, because it produces the same kind of electrical energy that the body uses. ... form of moving electrons. This flow of electrons out of the battery is generated ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response to ... Department of Health Care Services, will facilitate the development of a hub and ...
(Date:7/24/2017)... ... July 24, 2017 , ... Every year, thousands of dedicated Higher ... InstructureCon. Each annual event is coupled with a dynamic theme like Camp Canvas; this ... theme, Mission: InstructureCon 0017. , To extend their partnership with Canvas beyond the ...
(Date:7/24/2017)... Beach, California (PRWEB) , ... July 24, 2017 ... ... commercialization of autologous fat (adipose) transfer systems announces the issuance of United States ... ‘324 patent) for its adipose filtration technology. The '398 and '324 patents ...
(Date:7/24/2017)... ... July 24, 2017 , ... Paul Vitenas, MD, FACS is excited to report ... invited to attend Allergan’s recent meeting with their Plastics Advisory Board. As one of ... Allergan is bringing a newly defined structure to the aesthetics market. Dr. Vitenas ...
Breaking Medicine News(10 mins):
(Date:7/17/2017)... 17, 2017  MedX Holdings, Inc., the manufacturer and ... and rehabilitation equipment, today announced the national roll out ... considered the gold standard for the treatment of low ... strengthening equipment. How ... physician or practice who prescribe the MedX Home Back ...
(Date:7/13/2017)... 13, 2017  Centurion Medical Products, a leader in medical product ... fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part ... alleviate patient pain while preventing unneeded emergency department admission due to ...
(Date:7/12/2017)... INDIANAPOLIS , July 12, 2017  Eli Lilly and ... settlement agreement with generic companies to resolve pending patent litigation ... Virginia regarding the Cialis ® ... expire on April 26, 2020. As part of the agreement, ... on September 27, 2018. "The unit dose patent ...
Breaking Medicine Technology: